Myfortic

Pre-clinicalUNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 22/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Uveitis

Conditions

Uveitis

Trial Timeline

Jan 1, 2009 → Dec 1, 2011

NCT ID

NCT01261169

About Myfortic

Myfortic is a pre-clinical stage product being developed by Novartis for Uveitis. The current trial status is unknown. This product is registered under clinical trial identifier NCT01261169. Target conditions include Uveitis.

What happened to similar drugs?

3 of 20 similar drugs in Uveitis were approved

Approved (3) Terminated (8) Active (9)

🔄4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3

🔄Baricitinib + AdalimumabEli LillyPhase 3

✅Ixekizumab Prefilled SyringeEli LillyApproved

🔄adalimumabAbbViePhase 3

🔄Adalimumab + Prednisone + PlaceboAbbViePhase 3

✅AdalimumabAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04645589	Pre-clinical	Completed	Mar 16, 2021	Jun 13, 2025	Lupus Nephritis
NCT00652834	Approved	Completed	Apr 1, 2009	May 1, 2011	Gastrointestinal Lesions
NCT01261169	Pre-clinical	UNKNOWN	Jan 1, 2009	Dec 1, 2011	Uveitis
NCT00468936	Phase 3	UNKNOWN	May 1, 2007	Dec 1, 2009	Heart Transplant Patients
NCT00336895	Pre-clinical	Completed	Nov 1, 2006	Nov 1, 2008	Immunosuppression
NCT00676221	Approved	UNKNOWN	Jul 1, 2006	Sep 1, 2008	Kidney Transplant
NCT00298883	Phase 1	Completed	Feb 1, 2006	Dec 1, 2008	End Stage Renal Disease
NCT00167492	Approved	Withdrawn	Sep 1, 2005	Feb 1, 2009	Liver Transplantation
NCT00101738	Phase 3	Completed	Mar 1, 2003	May 1, 2005	Kidney Transplantation

Competing Products

20 competing products in Uveitis

See all competitors

Product	Company	Stage	Hype Score
triamcinolone acetonide (Triesence®)	Clearside Biomedical	Phase 1/2	22
4 mg CLS-TA Suprachoriodal Injection	Clearside Biomedical	Phase 3	30
Baricitinib + Adalimumab	Eli Lilly	Phase 3	44
Ixekizumab Prefilled Syringe	Eli Lilly	Approved	39
adalimumab	AbbVie	Phase 3	40
Adalimumab + Prednisone + Placebo	AbbVie	Phase 3	40
Adalimumab + Prednisone + Placebo	AbbVie	Phase 3	40
Adalimumab	AbbVie	Approved	43
FTY720 + Oral Corticosteroid	Novartis	Phase 2	27
AIN457	Novartis	Phase 3	32
AIN457 + AIN457 + Placebo AIN457	Novartis	Phase 3	32
LFG316 + Conventional Therapy	Novartis	Phase 2	35
Ranibizumab	Novartis	Phase 2	35
AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
AEB071	Novartis	Phase 2	35
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
Myfortic + Decortin	Novartis	Phase 3	40
AIN457 + AIN 457 + AIN457	Novartis	Phase 2	35
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32